cenobamate
Xcopri (cenobamate) is an anticonvulsant from SK Life Science for partial-onset seizures in adults. It calms hyperexcitable brain circuits by tempering sodium channel activity and boosting inhibitory GABA signalling, helping control seizures that persist despite other medicines.
This page is based on FDA prescribing information and the EMA medicine record for cenobamate, cross-checked with DailyMed and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A seizure is like feedback shrieking through a microphone and speaker loop. Cenobamate works two controls at once: it turns down the gain on the neurons that fire too eagerly, and it turns up the room's natural sound-dampening, so the squeal cannot build into a full storm.
In simple terms
Seizures happen when electrical activity in part of the brain becomes excessive and spreads. Cenobamate reduces this abnormal activity in two ways. It limits how strongly nerve cells can fire repeatedly by acting on sodium channels, and it strengthens the effect of GABA, the brain's main calming messenger. Together these actions keep runaway electrical storms from starting or spreading.
In depth
Cenobamate inhibits the persistent component of voltage-gated sodium current, reducing repetitive neuronal firing, and acts as a positive allosteric modulator of GABA-A receptors at a site distinct from benzodiazepines and barbiturates, enhancing inhibitory tone. This dual mechanism differentiates it from many older antiseizure drugs and is associated with notable seizure-freedom rates in treatment-resistant focal epilepsy. Dose titration is gradual to minimise the risk of hypersensitivity reactions.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
Cenobamate works two controls at once
- Seizures happen when electrical activity in part of the brain becomes excessive and spreads.
- Cenobamate reduces this abnormal activity in two ways.
- It limits how strongly nerve cells can fire repeatedly by acting on sodium channels, and it strengthens the effect of GABA, the brain's main calming messenger.
- Together these actions keep runaway electrical storms from starting or spreading.
Target: Voltage-gated sodium channels and GABA-A receptors
Sodium channels let neurons fire rapid electrical bursts, while GABA-A receptors apply the brain's natural braking signal; seizures arise when excitation outruns inhibition.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of partial-onset seizures in adult patients
Approved uses in European Union
EMA- Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults with epilepsy that has not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products
Official sources
The statements on this page trace back to these records.
- Ontozry (cenobamate) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Xcopri (cenobamate) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: cenobamate prescribing information
U.S. Food and Drug Administration
- MedlinePlus: cenobamate
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.